



FILE COPY

Receipt

Patent  
030586.0009.CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Vincent P. Stanton, Jr.

Serial No.: 09/648,123

Filed: August 25, 2000

For: GENE SEQUENCE VARIATIONS  
WITH UTILITY IN DETERMINING  
THE TREATMENT OF DISEASE, IN  
GENES RELATING TO DRUG  
PROCESSING

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

During a review of the Official Filing Receipt, Attorney for Applicant noted that the Continuing Data as Claimed by Applicant, and Title are incorrect on the filing receipt.

(1) The Filing Receipt shows the Continuing Data as Claimed by Applicant as:

"This application is a CIP of 09/590,748  
Which is a CIP of 09/501,955 02/10/2000  
Which is a CIP of PCT/US00/01392 01/20/2000  
Which is a CIP of 09/427,835 10/26/1999  
Which is a CIP of 09/300,747 04/26/1999

RECEIVED  
MAR 19 2001  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

December 14, 2000  
Date of Deposit

Jason Berry  
Name of Person Mailing Paper

Jason Berry  
Signature of Person Mailing Paper



Patent  
030586.0009.CIP2

Which claims Benefit of 60/131,334 04/26/1999  
and Claims Benefit of 60/139,440 06/15/1999"

However, the Continuing Data as Claimed by Applicant should be changed to read as follows:

**--This Application is a CIP of 09/590,748 06/08/2000  
Which is a CIP of 09/501,955 02/10/2000  
Which is a CIP of PCT/US00/01392 01/20/2000  
and is a CIP of 09/427,835 10/26/1999  
and is a CIP of 09/300,747 04/26/1999  
Which Claims Benefit of 60/131,334 04/26/1999  
and Claims Benefit of 60/139,440 06/15/1999--.**

(2) Additionally, the Title of the application on the filing receipts read as:

"Gene sequence variations with utility in determining the treatment disease, in  
genes relating to drug processing"

However, the Title of the assignment should be changed to read as follows:

--Gene sequence variations with utility in determining the treatment of disease, in  
genes relating to drug processing--

Please make the aforementioned correction to the filing receipt. No fee is  
believed due with this filing but if any fee is required, please charge our Deposit Account No.  
50-1273 for the appropriate amount.

Respectfully submitted,


Brobeck, Phleger & Harrison LLP

Dated: 14 December 2000

By: Wesley B. Ames  
Wesley B. Ames  
Registration No. 40,8

Brobeck, Phleger & Harrison LLP  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 720-2500  
Facsimile: (858) 720-2555

RECEIVED  
MAR 19 2001  
TECH CENTER  
1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
NOV 30 2000  
COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/648,123	08/25/2000	1645	345	030586.0009.CIP2		16	3

Brobeck Phleger & Harrison LLP  
12390 El Camino Real  
San Diego, CA 92130

## FILING RECEIPT



\*OC000000005569767\*

Date Mailed: 11/21/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Vincent P. Stanton JR., Belmont, MA ;

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/590,783 06/08/2000  
WHICH IS A CIP OF 09/501,955 02/10/2000  
WHICH IS A CIP OF PCT/US00/01392 01/20/2000  
WHICH IS A CIP OF 09/427,835 10/26/1999 \*  
WHICH IS A CIP OF 09/300,747 04/26/1999  
WHICH CLAIMS BENEFIT OF 60/131,334 04/26/1999  
AND CLAIMS BENEFIT OF 60/139,440 06/15/1999  
(\* ) Data inconsistent with PTO records.

## Foreign Applications

If Required, Foreign Filing License Granted 11/20/2000

\*\* SMALL ENTITY \*\*

## Title

Gene sequence variations with utility in determining the treatment disease, in genes relating to drug processing

## Preliminary Class

424

RECEIVED  
MAR 19 2001  
TECH CENTER 1600/2900

Data entry by : BRITTON, PAULA

Team : OIRE

Date: 11/21/2000





**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

**RECEIVED**  
MAR 19 2001  
TECH CENTER 1600/2900

**THIS PAGE BLANK (USPTO)**